Drug intelligence / Profile preview

GLP-1 receptor agonist (Saya Bio)

Development stage: Preclinical
Lead developer: Saya Biologics
Modality: Peptides

Overview

Saya Bio's GLP-1 receptor agonist is a peptide-based therapeutic currently in preclinical development for the treatment of type 2 diabetes. It functions as an agonist of the glucagon-like peptide-1 (GLP-1) receptor, mimicking the physiological action of the endogenous incretin hormone GLP-1. The drug's mechanism of action involves enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon secretion, and slowing gastric emptying, which collectively lead to improved glycemic control. This asset is part of Saya Bio's broader pipeline of peptide therapeutics and biosimilars targeting metabolic and chronic diseases.

Other names: GLP-1 RAGLP1 RAGLP 1 RAGLP-1 receptor agonist (peptide)

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on GLP-1 receptor agonist (Saya Bio).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLP-1 receptor agonist (Saya Bio).

Explore the full profile